TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32819157

Group type: EXPERIMENTAL
Intervention: Intraobserver reliability measurement of HVI angle
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Interobserver reliability measurement of HVI angle
Number of subjects: 16

Group type: COMPARATOR
Intervention: Surgeons' level of experience
Number of subjects: 16
Study: 32417634

Group type: EXPERIMENTAL
Intervention: Selenium yeast (200 μg/day) and coenzyme Q10 (200 mg/day)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 32995961

Group type: EXPERIMENTAL
Intervention: Eccentric quasi-isometric (EQI) contractions
Number of subjects: 15

Group type: COMPARATOR
Intervention: Isokinetic eccentric (ECC) contractions
Number of subjects: 15
Study: 33038664

Group type: EXPERIMENTAL
Intervention: Periodontitis
Number of subjects: 22
Study: 34753667

Group type: EXPERIMENTAL
Intervention: Multi-component school-based intervention (weekly supervised circuit exercise 30 min/week, health education session 10 min/week, lunchtime sports activities 20 min/week)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Multi-component school-based intervention
Number of subjects: 160
Study: 33179822

Group type: EXPERIMENTAL
Intervention: 3D magnetic resonance fingerprinting with quadratic RF phase (qRF‐MRF)
Number of subjects: 0
Study: 32563378

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g loading dose followed by 3 g maintenance dose over 24 hours)
Number of subjects: 12009

Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 12009

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 12009

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12009
Study: 35147195

Group type: EXPERIMENTAL
Intervention: G-CSF (300 µg, 1.8 ml)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Normal saline (1.8 ml)
Number of subjects: 245
Study: 34732440

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESP Block)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Serratus plane block (SPB) plus pectoral nerve blocks (PECS I)
Number of subjects: 104
Study: 32921096

Group type: EXPERIMENTAL
Intervention: HX110-A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HX110-B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 35945818

Group type: EXPERIMENTAL
Intervention: DCB-only group (n = 36)
Number of subjects: 85

Group type: COMPARATOR
Intervention: DES group (n = 49)
Number of subjects: 85
Study: 32719354

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Resistance Training (RES)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 72
Study: 1997163897

Group type: EXPERIMENTAL
Intervention: Aprotinin (2000000 IU as a bolus + 500000 JU/h until the end of the operation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 36437523

Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Higher intake of whole grain cereals, fruits, vegetables, and fish; lower intake of sweets
Number of subjects: 152
Study: 33512413

Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 401
Study: 32681911

Group type: EXPERIMENTAL
Intervention: Induced WTR astigmatism (1-D increase)
Number of subjects: 15
Study: 34294550

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (50,000 IU weekly for 12 weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 34269257

Group type: EXPERIMENTAL
Intervention: Ketamine infusion of 1 mg/kg/h
Number of subjects: 64

Group type: COMPARATOR
Intervention: Propofol infusion of 1.5-6 mg/kg/h
Number of subjects: 64
Study: 32101145

Group type: EXPERIMENTAL
Intervention: Preoperative forced-air and intravenous fluid warming
Number of subjects: 135

Group type: COMPARATOR
Intervention: No active warming
Number of subjects: 135
Study: 35883082

Group type: EXPERIMENTAL
Intervention: Menaquinone‐7 (90 µg/day)
Number of subjects: 84
Study: 32769826

Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training (CCT)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 123
Study: 32075666

Group type: EXPERIMENTAL
Intervention: 20 kHz stimulation
Number of subjects: 14
Study: 36196478

Group type: EXPERIMENTAL
Intervention: FEP-medication group (second-generation antipsychotic medication)
Number of subjects: 81

Group type: COMPARATOR
Intervention: FEP-placebo group
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: FEP-medication group
Number of subjects: 81
Study: 34807661

Group type: EXPERIMENTAL
Intervention: Faster within-treatment improvement of PTSD symptoms
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Full-time employment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Age and speed of PTSD improvement interaction
Number of subjects: 70
Study: 36242831

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU), twice daily for three days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 32610330

Group type: EXPERIMENTAL
Intervention: Cold Therapy (CT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study: 34461950

Group type: EXPERIMENTAL
Intervention: Immediate FET (first menstrual cycle after failed IVF-ET)
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Immediate FET
Number of subjects: 732
Study: 32832550

Group type: EXPERIMENTAL
Intervention: TACIA score (new prognostic model)
Number of subjects: 308
Study: 34967801

Group type: COMPARATOR
Intervention: Continuous exercise training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Continuous plus HIIT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Continuous plus BFR training combined with HIIT (BFRIT)
Number of subjects: 50
Study: 33397767

Group type: EXPERIMENTAL
Intervention: Bihormonal artificial pancreas (AP) therapy, 2-week duration
Number of subjects: 23

Group type: COMPARATOR
Intervention: Open loop control (patient's normal insulin pump therapy), 2-week duration
Number of subjects: 23
Study: 33368617

Group type: EXPERIMENTAL
Intervention: 15 mg diazepam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32044942

Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy (n=785)
Number of subjects: 1548

Group type: COMPARATOR
Intervention: Standard wound dressing (n=763)
Number of subjects: 1548
Study: 33522891

Group type: EXPERIMENTAL
Intervention: Ice slurry ingestion (1.25 g·kg body mass‐1 at -1°C) during HA training
Number of subjects: 7

Group type: COMPARATOR
Intervention: Room temperature beverage ingestion (NOC: 36.5°C) during HA training
Number of subjects: 7
Study: 34633434

Group type: EXPERIMENTAL
Intervention: Multidomain interventions targeting vascular risk factors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33310053

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control
Number of subjects: 155
Study: 35964000

Group type: EXPERIMENTAL
Intervention: Eight-week mindfulness program
Number of subjects: 150

Group type: COMPARATOR
Intervention: Eight-week, placebo-controlled lifestyle education program
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mindfulness program
Number of subjects: 150
Study: 34167523

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) intervention conducted in eight 90-min sessions
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study: 32817701

Group type: EXPERIMENTAL
Intervention: Shared Care (SC)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 700
Study: 36039657

Group type: EXPERIMENTAL
Intervention: GP2017-HCF
Number of subjects: 330

Group type: COMPARATOR
Intervention: GP2017
Number of subjects: 330
Study: 33905343

Group type: EXPERIMENTAL
Intervention: Sitting with 6-min simple resistance activities (SRA6) every 60 min
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sitting with 3-min simple resistance activities (SRA3) every 30 min
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sitting uninterrupted for 7 hours (SIT)
Number of subjects: 23
Study: 36198994

Group type: EXPERIMENTAL
Intervention: Fluconazole (150 mg) with 30 placebo capsules of probiotic
Number of subjects: 80

Group type: COMPARATOR
Intervention: Probiotic (30 capsules containing 1 × 10^9 CFU/g LA‐5) with 1 fluconazole placebo capsule
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 80

Group type: COMPARATOR
Intervention: Probiotic
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fluconazole and Probiotic
Number of subjects: 80
Study: 32701225

Group type: EXPERIMENTAL
Intervention: Ocriplasmin infusion during robot-assisted retinal vein cannulation
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ocriplasmin infusion
Number of subjects: 4
Study: 32865145

Group type: EXPERIMENTAL
Intervention: DCB (MDT-2113, IN.PACT Admiral)
Number of subjects: 100

Group type: COMPARATOR
Intervention: PTA (Percutaneous Transluminal Angioplasty)
Number of subjects: 100
Study: 35247321

Group type: EXPERIMENTAL
Intervention: ZY-19489 1500 mg
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ZY-19489 (300 mg) in fed state
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ZY-19489 (300 mg) in fasted state
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ZY-19489 (200 mg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ZY-19489 (300 mg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ZY-19489 (900 mg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic-Pharmacodynamic model simulation for 1100 mg
Number of subjects: 71
Study: 32962980

Group type: EXPERIMENTAL
Intervention: PAM50MET-low
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: PAM50MET-high
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: PAM50MET-low (BOLERO-2)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: PAM50MET-high (BOLERO-2)
Number of subjects: 484
Study: 33301819

Group type: EXPERIMENTAL
Intervention: Video group (n = 58)
Number of subjects: 107
Study: 32005622

Group type: EXPERIMENTAL
Intervention: IPACK block
Number of subjects: 69
Study: 35450456

Group type: EXPERIMENTAL
Intervention: 0.30% sodium hyaluronate ocular gel
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.18% sodium hyaluronate eye drops
Number of subjects: 70
Study: 33561455

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥ 30 kg/m2)
Number of subjects: 2325

Group type: COMPARATOR
Intervention: Nonobese patients (BMI < 30 kg/m2)
Number of subjects: 2325
Study: 35749525

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT)
Number of subjects: 1743

Group type: COMPARATOR
Intervention: No postmastectomy radiotherapy (no-PMRT)
Number of subjects: 1743

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT) in patients with three nodes positive
Number of subjects: 1743

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT) in patients with one or two nodes positive
Number of subjects: 1743

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT) in TNBC patients with T2 tumor and three positive lymph nodes
Number of subjects: 1743
Study: 32962443

Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35612589

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Amerindian ethnicity
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Group 3 (head and neck-limited)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Overall clinical and serological features
Number of subjects: 184
Study: 35445520

Group type: EXPERIMENTAL
Intervention: SlowMo therapy
Number of subjects: 22
Study: 33509389

Group type: EXPERIMENTAL
Intervention: Slit-lamp model for screening hepatobiliary diseases
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Fundus model for screening hepatobiliary diseases
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Slit-lamp model for identifying liver cancer
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Fundus model for identifying liver cancer
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Slit-lamp model for identifying liver cirrhosis
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Fundus model for identifying liver cirrhosis
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Slit-lamp model for identifying other hepatobiliary diseases
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Fundus model for identifying other hepatobiliary diseases
Number of subjects: 1252
Study: 32541398

Group type: EXPERIMENTAL
Intervention: Parent-based, ROM-assisted group psychotherapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 25
Study: 35780790

Group type: EXPERIMENTAL
Intervention: Offer of bandage group
Number of subjects: 965

Group type: COMPARATOR
Intervention: Rigid immobilisation group
Number of subjects: 965
Study: 34637332

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 6564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6564
Study: 34648352

Group type: EXPERIMENTAL
Intervention: FOLFOX‐HAIC (oxaliplatin 130 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2 on day 1, and fluorouracil infusion 2,400 mg/m2 for 24 hours, once every 3 weeks)
Number of subjects: 315

Group type: COMPARATOR
Intervention: TACE (epirubicin 50 mg, lobaplatin 50 mg, and lipiodol and polyvinyl alcohol particles)
Number of subjects: 315
Study: 34336000

Group type: EXPERIMENTAL
Intervention: Deep-Learning Genomics (DLG) model
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Traditional GWAS analysis
Number of subjects: 1461
Study: 33201116

Group type: EXPERIMENTAL
Intervention: sNPWT dressing
Number of subjects: 146

Group type: COMPARATOR
Intervention: Conventional dressing
Number of subjects: 146
Study: 32746835

Group type: EXPERIMENTAL
Intervention: Primary tumor resection (PTR)
Number of subjects: 9143

Group type: COMPARATOR
Intervention: No primary tumor resection (non-PTR)
Number of subjects: 9143
Study: 34246153

Group type: EXPERIMENTAL
Intervention: Augmented reality app (six 30‐min sessions at home over a two‐week period)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 66
Study: 35797108

Group type: EXPERIMENTAL
Intervention: Growth Assessment Protocol (GAP)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 13
Study: 32134128

Group type: EXPERIMENTAL
Intervention: Preoperative simple transfusion
Number of subjects: 138

Group type: COMPARATOR
Intervention: No transfusion
Number of subjects: 138
Study: 35237342

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin combined with vitamin E
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 134
Study: 34701332

Group type: EXPERIMENTAL
Intervention: S1 maintenance therapy
Number of subjects: 183

Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 183
Study: 33228899

Group type: EXPERIMENTAL
Intervention: Noise-canceling headphones (NCHs) with music
Number of subjects: 490

Group type: COMPARATOR
Intervention: Non-NCH hearing protection alone
Number of subjects: 490
Study: 34856826

Group type: EXPERIMENTAL
Intervention: Acupuncture (standardized protocol, twice per week for 5 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Attention control protocol
Number of subjects: 24
Study: 34678887

Group type: EXPERIMENTAL
Intervention: Epidural block with 75 mg of bupivacaine plus 50 μg of fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 15 mg of bupivacaine and 50 μg fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Saddle block with 15 mg of bupivacaine and 50 μg of fentanyl
Number of subjects: 60
Study: 32808455

Group type: COMPARATOR
Intervention: Person-centred care interventions
Number of subjects: 27
Study: 36448475

Group type: EXPERIMENTAL
Intervention: Standard self-monitoring with no microinterventions
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Skills monitoring with no microinterventions
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Standard self-monitoring with automated microinterventions
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Skills monitoring with automated microinterventions
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Standard self-monitoring with just-in-time adaptive interventions
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Skills monitoring with just-in-time adaptive interventions
Number of subjects: 264
Study: 34284312

Group type: EXPERIMENTAL
Intervention: JUUL e‐cigarettes
Number of subjects: 187

Group type: COMPARATOR
Intervention: Cigarettes as usual
Number of subjects: 187
Study: 35907175

Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate/ursodoxicoltaurine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33137150

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (2005 International Diabetes Federation criteria)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (revised ATP III criteria)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (2009 harmonized criteria)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Consumption of red meat
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Sedentary leisure time activity
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Coffee intake
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: BMI ≥ 25 kg/m2
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Age 40-49 years
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Age 50-59 years
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Age ≥ 70 years
Number of subjects: 343
Study: 34768161

Group type: EXPERIMENTAL
Intervention: Interferon‐α + Sargramostim (IFN)
Number of subjects: 34

Group type: COMPARATOR
Intervention: K562/GM‐CSF vaccine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Adjuvant IFN (including crossover)
Number of subjects: 34
Study: 32087684

Group type: EXPERIMENTAL
Intervention: Oral Sucrosomial® iron
Number of subjects: 99

Group type: COMPARATOR
Intervention: Intravenous (IV) iron gluconate
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cost comparison
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis
Number of subjects: 99
Study: 33973256

Group type: EXPERIMENTAL
Intervention: Faces with distinctive features (e.g., tattoos)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Faces without distinctive features
Number of subjects: 0
Study: 33245807

Group type: EXPERIMENTAL
Intervention: Cues to experience nature (e.g., smell flowers, observe wildlife, turn off your phone)
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Cues to experience nature (e.g., smell and touch natural elements)
Number of subjects: 1023
Study: 35139101

Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Written summary of evidence
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (no information)
Number of subjects: 234
Study: 34557142

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (INDAK, nutrition counseling, vascular risk management)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Usual vascular care advice and referral (Control)
Number of subjects: 605
Study: 33371022

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation (4-6 weeks) including exercise training, nutrition counselling, respiratory physiotherapy, and mindfulness sessions
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 160
Study: 35135308

Group type: EXPERIMENTAL
Intervention: Uninterrupted apixaban
Number of subjects: 674

Group type: COMPARATOR
Intervention: Vitamin K antagonist therapy
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Uninterrupted apixaban and Vitamin K antagonist therapy
Number of subjects: 674
Study: 33508849

Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Lanreotide autogel
Number of subjects: 535

Group type: COMPARATOR
Intervention: Lanreotide
Number of subjects: 535
Study: 35278201

Group type: EXPERIMENTAL
Intervention: Microwell group culture
Number of subjects: 532
Study: 32196696

Group type: EXPERIMENTAL
Intervention: PRIRATE guidelines checklist and flowchart
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: PRIRATE guidelines
Number of subjects: 51
Study: 34533841

Group type: EXPERIMENTAL
Intervention: Biperiden (4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35713447

Group type: EXPERIMENTAL
Intervention: Institutional antiemetic therapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Institutional antiemetic therapy in combination with ginger (2 different concentrations)
Number of subjects: 0
Study: 35790016

Group type: COMPARATOR
Intervention: Standard chemotherapy (control arm of five RCTs: ASCENT 2, VENICE, CELGENE/MAINSAIL, ENTHUSE 14, ENTHUSE 33)
Number of subjects: 2336
Study: 33792400

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-exercising Control
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MICT and HIIT
Number of subjects: 28
Study: 32374442

Group type: EXPERIMENTAL
Intervention: Case-based learning (CBL)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Lecture-based learning (LBL)
Number of subjects: 2
Study: 36054319

Group type: EXPERIMENTAL
Intervention: Combined Calcipotriol/Betamethasone foam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Betamethasone foam alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clobetasol Propionate ointment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32202920

Group type: EXPERIMENTAL
Intervention: Our Family Our Future intervention
Number of subjects: 73

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 73